Improved Orthopedic Implant Surface Coatings

改进的骨科植入物表面涂层

• 批准号: 6882324
• 负责人: PAUL T HAMILTON
• 金额: $ 21.43万
• 依托单位: AFFINERGY ,INC
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-01 至 2006-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6882324
• 关键词: biomaterial compatibility; biomaterial development /preparation; biomaterial evaluation; biomaterial interface interaction; implant; laboratory rat; medical implant science; orthopedics; surface coating; titanium

Endosseous metallic implants are common alloplastic devices used in medicine and dentistry. The orthopedic and dental marketplace continues to grow and indications for implants are expanding. There is a perceived need to improve both the successful healing (osseointegration) and the long term outcome of implants by control of interfacial reactivity during healing and remodeling. The growth of knowledge of bone biology and the expansion of biotechnology permits the present consideration of specifying one or more interfacial biologic activities to an endosseous metallic implant by use of a natural or synthetic bioactive agent (growth factor, extracellular matrix protein, small molecule). Potential examples of relevant interfacial actions include osteoinduction specified by BMPs, inhibition of resorption specified by OPG, inhibition of inflammation TNFR antagonists, or prevention of infection by anti-microbial or anti-fouling molecules. Each interfacial action is of related significance to one or more endosseous metallic implant application used today. The main obstacle facing the direct specification of a biological activity or activities to an endosseous metallic implant surface is the attachment of the specifying agent to the metallic surface without compromising the underlying mechanical properties of the implant or the function of the specifying bioactive agent. In this proposal we present a novel approach for specifying the biologic activity of titanium implant surfaces. Affinergy has developed a generalized approach to creating target surface-specific biopolymers that irreversibly bind specifying bioactive agents to the endosseous implant surface. These specifying and grafting biopolymers are termed a "interfacial biomaterials" (IFBM). The bi-functional IFBM has the unique advantages of a) providing requisite surface binding specificity, b) comprising robust chemistry for broad-based applications and c) offering capacity to specify a wide range of associated or independent biological activities onto a single metallic surface. The goal of this phase I SBIR proposal is to validate the IFBM approach to specifying a biological activity to titanium endosseous implants. The results of this research will establish the foundation for direct translation of IFBM-modified endosseous implants to clinical applications.

内质金属植入物是医学和牙科中使用的常见同种异体设备。这 骨科和牙科市场不断增长，植入物的迹象正在扩大。人们需要通过控制愈合和重塑过程中的界面反应性来改善成功的愈合（骨整合）和植入物的长期结局。骨骼生物学知识的增长和生物技术的扩展允许当前考虑通过使用天然或合成生物活性剂（生长因子，细胞外基质蛋白，小分子）将一种或多种界面生物学活性指定为内体金属植入物。相关界面作用的潜在例子包括BMPS指定的骨诱导，抑制OPG指定的吸收，抑制 炎症TNFR拮抗剂，或预防抗微生物或抗污染分子感染。每种界面作用与当今使用的一种或多种内质金属植入物应用都具有相关意义。直接指定生物活性或活动到内质金属植入物表面的主要障碍物是指定剂在金属表面上的附着，而不会损害植入物的基本机械性能或指定生物活性剂的功能。 在此提案中，我们提出了一种新的方法，用于指定钛植入物表面的生物学活性。 Affinergy开发了一种普遍的方法来创建目标表面特异性生物聚合物，该聚合物不可逆地将定义生物活性剂与内质植入物表面结合。这些指定和嫁接的生物聚合物称为“界面生物材料”（IFBM）。双功能IFBM具有a）提供必要的表面结合特异性的独特优势，b）包括针对广泛应用的鲁棒化学和c）提供指定各种相关或独立生物学的能力 活在单个金属表面上。该阶段I SBIR提案的目的是验证IFBM的方法，以指定钛植入钛植入物的生物活性。这项研究的结果将为直接翻译IFBM修饰的内对植入物为临床应用而建立基础。

项目成果

Improved bone morphogenetic protein-2 retention in an injectable collagen matrix using bifunctional peptides.

• DOI: 10.1371/journal.pone.0070715
• 发表时间: 2013
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Hamilton PT;Jansen MS;Ganesan S;Benson RE;Hyde-Deruyscher R;Beyer WF;Gile JC;Nair SA;Hodges JA;Grøn H
• 通讯作者: Grøn H